Upgrade to SI Premium - Free Trial

InflaRx N.V. (IFRX)

1.81 -0.01 (0.55%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form SCHEDULE 13G InflaRx N.V. Filed by: Farallon Capital Partners, L.P. May 14, 2026 8:28 AM - SEC Filing Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy May 13, 2026 7:15 AM - StreetInsider Form SCHEDULE 13G InflaRx N.V. Filed by: TCG Crossover GP III, LLC May 12, 2026 6:03 PM - SEC Filing InflaRx completes $150 million share offering at $2.00 per share May 8, 2026 8:17 AM - StreetInsider InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares May 8, 2026 8:15 AM - Globe NewsWire Form 6-K InflaRx N.V. For: May 07 May 7, 2026 4:02 PM - SEC Filing Form 424B5 InflaRx N.V. May 7, 2026 8:34 AM - SEC Filing Form 424B5 InflaRx N.V. May 6, 2026 4:01 PM - SEC Filing Form 6-K InflaRx N.V. For: May 06 May 6, 2026 8:34 AM - SEC Filing InflaRx prices $150 million stock offering at $2 per share May 6, 2026 8:31 AM - StreetInsider InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares May 6, 2026 8:30 AM - Globe NewsWire InflaRx advances izicopan development for kidney diseases May 6, 2026 8:26 AM - StreetInsider InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases May 6, 2026 8:25 AM - Globe NewsWire Form 6-K InflaRx N.V. For: Mar 31 May 6, 2026 8:09 AM - SEC Filing Form 6-K InflaRx N.V. For: May 04 May 4, 2026 4:29 PM - SEC Filing InflaRx shows lower reactive metabolite formation for izicopan vs avacopan May 4, 2026 7:31 AM - StreetInsider InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes May 4, 2026 7:30 AM - Globe NewsWire InflaRx to Report First Quarter 2026 Results on May 7, 2026 May 1, 2026 7:30 AM - Globe NewsWire iFOREX Lists on London Stock Exchange, offering Cryptocurrency trading (CFDs) Across Global and LATAM Markets April 29, 2026 3:30 AM - PR NewsWire Form 6-K InflaRx N.V. For: Apr 28 April 28, 2026 4:17 PM - SEC Filing InflaRx regains Nasdaq minimum bid price compliance April 28, 2026 7:30 AM - StreetInsider InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement April 28, 2026 7:30 AM - Globe NewsWire Oppenheimer Assumes Inflarx NV (IFRX) at Outperform April 24, 2026 6:15 AM - StreetInsider Form 6-K InflaRx N.V. For: Apr 23 April 23, 2026 7:06 PM - SEC Filing Guggenheim Reiterates Buy Rating on Inflarx NV (IFRX) April 21, 2026 6:51 AM - StreetInsider Form 6-K InflaRx N.V. For: Apr 09 April 9, 2026 4:31 PM - SEC Filing InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor April 9, 2026 7:30 AM - StreetInsider Form 6-K InflaRx N.V. For: Apr 02 April 2, 2026 4:19 PM - SEC Filing InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium March 31, 2026 7:30 AM - StreetInsider InflaRx presents vilobelimab data for pyoderma gangrenosum at AAD meeting March 30, 2026 7:30 AM - StreetInsider InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting March 30, 2026 7:30 AM - StreetInsider Full Article List